Abstract Context The European Association of Urology Renal Cell Carcinoma Guideline
Panel recently conducted a systematic review of treatment options for patients with …

Background: About 40% of metastatic clear-cell renal cell carcinoma (m-ccRCC) patients
receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor …

Introduction: Non-clear cell renal cell carcinoma (nccRCC) represents a highly
heterogenous group of kidney cancer entities. As most clinical trials predominantly include …

Opinion statement The treatment for metastatic renal cell carcinoma (mRCC) has
significantly evolved in recent years with a deeper understanding of the molecular make-up …

Treatment options for metastatic renal cell carcinoma (RCC) continue to expand. Three
recent phase III trials, Checkmate 214, Keynote-426, and Javelin Renal 101, have led to …

The optimal management approach to advanced or metastatic renal cell cancer of the clear
cell type continues to rapidly evolve. Risk stratification of patients into favorable …

Simple Summary Despite the continuous therapeutic efforts metastatic renal cell carcinoma
(mRCC) is a dreadful disease, but the many options available provide an horizon of hope for …

United States–based epidemiologic studies indicate that more than 70,000 individuals are
diagnosed with renal cell carcinoma (RCC) annually, and 17% of these present with …

Given the underrepresentation of older patients in registration trials for metastatic renal cell
carcinoma (mRCC), data to support the use of any particular systemic therapy over others …

Non–clear cell renal cell carcinoma (nccRCC) is a broad term that refers to a diverse group
of tumors, each with its own distinct biologic and therapeutic profile. The management of …